Linked Life Data

18067633

Source:http://linkedlifedata.com/resource/pubmed/id/18067633

Statements in which the resource exists as a subject.
PredicateObject
rdf:type
lifeskim:mentions
pubmed:dateCreated
2007-12-10
pubmed:abstractText
External genital and anal warts (acuminate condyloma) were the first medical indication the topical immune response modifier imiquimod was approved for in 1997. Since then, many placebo controlled randomized clinical trials have demonstrated the efficacy and safety of this synthetic imidazoquinoline derivate for the treatment of different human papillomavirus infections and tumours. Treatment modalities for genital warts (5% cream, three times weekly, minimum duration 4 weeks, control of side-effects) have been optimized and assured by further clinical trials and meta-analyses. For a few years clinical studies focussed on the long-term efficacy of the immunomodulatory therapy (sustained clearance from warts) and most recent studies compared the efficacy of ablative, destructive and imiquimod monotherapy as well as combination therapies.
pubmed:language
eng
pubmed:journal
pubmed:citationSubset
IM
pubmed:chemical
pubmed:status
MEDLINE
pubmed:month
Dec
pubmed:issn
0007-0963
pubmed:author
pubmed:issnType
Print
pubmed:volume
157 Suppl 2
pubmed:owner
NLM
pubmed:authorsComplete
Y
pubmed:pagination
52-5
pubmed:meshHeading
pubmed:year
2007
pubmed:articleTitle
Evaluation of imiquimod for the therapy of external genital and anal warts in comparison with destructive therapies.
pubmed:affiliation
Department of Dermatology and Venerology, University Hospital, J.W. Goethe University, Theodor-Stern-Kai 7, 60590 Frankfurt/M, Germany. Schoefer@em.uni-frankfurt.de
pubmed:publicationType
Journal Article, Comparative Study, Review, Research Support, Non-U.S. Gov't